Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction (DIAMONDHFpEF)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

280 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators wish to test a hypothesis that patients with HFpEF have different characteristics on echo, cardiac MRI and plasma protein \& chemical profiles compared to HFrEF and healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF

NCT06316661

Microvascular Coronary Artery Disease Heart Failure With Reduced Ejection Fraction

RECRUITING

Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging

NCT04602338

Heart Failure, Diastolic Multicenter Study

RECRUITING

Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction

NCT06652763

Heart Failure With Preserved Ejection Fraction Type 2 Diabetes

RECRUITING

Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR

NCT05114785

Heart Failure With Preserved Ejection Fraction Heart Diseases

NOT_YET_RECRUITING

Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

NCT04603404

Heart Failure, Diastolic

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Large scale prospective studies incorporating cardiac MRI, echocardiography and plasma sampling are currently lacking in HFpEF. The main aims of our study are to:

1. better phenotype and characterise HFpEF (also comparing with HFrEF and age- and sex- matched healthy controls)
2. provide mechanistic insights into pathophysiology
3. describe potential biomarkers and their relation to relevant clinical outcomes (exercise capacity, heart failure quality of life and prognosis)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Patients With Heart Failure and Preserved Ejection Fraction - HFpEF Patients With Heart Failure With Reduced Ejection Fraction - HFrEF Healthy Controls Group - Age and Sex-matched

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HFpEF group

clinical or radiographic evidence of heart failure and left ventricular ejection fraction \> 50% on transthoracic echocardiography

MRI scan, Echo scan

Intervention Type DIAGNOSTIC_TEST

HFrEF group

Clinical or radiographic evidence of heart failure and left ventricular ejection fraction \< 40% on transthoracic echocardiography

MRI scan, Echo scan

Intervention Type DIAGNOSTIC_TEST

Healthy control group

Asymptomatic controls (age and sex-matched) without known heart disease

MRI scan, Echo scan

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI scan, Echo scan

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cardiac MRI, trans thoracic echocardiography

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical features of heart failure or prior radiographic evidence in the absence of symptoms And Either ejection fraction \> 50% (for HFpEF arm) or ejection fraction \< 40% (for HFrEF arm)

Exclusion Criteria

* Myocardial infarction within the preceding 6 months
* Suspected or confirmed cardiomyopathy (e.g. hypertrophic, infiltrative)
* Suspected or confirmed constrictive pericarditis
* Significant native valve disease (≥ moderate severity)
* Known Significant lung disease (documented or FEV1\< 30% or FVC \< 50%)
* Non-cardiovascular co-morbidity likely to cause death within 6 months (e.g. malignancy)
* Significant renal failure (estimated GFR \< 30 ml/min/m2)
* Patient inability to provide informed consent (e.g. dementia)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes